Satralizumab Treatment in Chinese Patients with AQP4-ab-positive Neuromyelitis Optica Specturm Disorder: A Prospective Study (P9-1.015)
To estimate the efficacy and safety of satralizumab in a prospective population of Chinese patients with AQP4+ NMOSD.
Authors
- Wenjuan Huang (ORCID: https://orcid.org/0000-0002-8056-373X)
- Qiang Dong (ORCID: https://orcid.org/0000-0003-1986-8961)
- Jingzi ZhangBao (ORCID: https://orcid.org/0000-0002-5308-6325)
- Chao Quan (ORCID: https://orcid.org/0000-0003-1040-3930)
Institutions
- Fudan University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211195
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.00